In Vivo Emergence of Pandrug-Resistant Acinetobacter baumannii Strain: Comprehensive Resistance Characterization and Compassionate Use of Sulbactam-Durlobactam.

Autor: VanNatta M; Department of Pharmacy, Ochsner LSU Health Shreveport, Shreveport, Louisiana, USA., Grier L; Division of Critical Care Medicine, LSU Health Shreveport, Shreveport, Louisiana, USA., Khan MH; Division of Infectious Diseases, Department of Medicine, LSU Health Shreveport, Shreveport, Louisiana, USA., Pinargote Cornejo P; Division of Infectious Diseases, Department of Medicine, LSU Health Shreveport, Shreveport, Louisiana, USA., Alam M; Division of Infectious Diseases, Department of Medicine, LSU Health Shreveport, Shreveport, Louisiana, USA., Moussa SH; Innoviva Specialty Therapeutics, Inc, an affiliate of Entasis Therapeutics Inc, Waltham, Massachusetts, USA., Smith JG; Department of Pharmacy, Ochsner LSU Health Shreveport, Shreveport, Louisiana, USA., Aitken SL; Department of Pharmacy, Michigan Medicine, Ann Arbor, Michigan, USA., Malek AE; Division of Infectious Diseases, Department of Medicine, LSU Health Shreveport, Shreveport, Louisiana, USA.
Jazyk: angličtina
Zdroj: Open forum infectious diseases [Open Forum Infect Dis] 2023 Oct 06; Vol. 10 (10), pp. ofad504. Date of Electronic Publication: 2023 Oct 06 (Print Publication: 2023).
DOI: 10.1093/ofid/ofad504
Abstrakt: The treatment of patients with infection secondary to carbapenem-resistant Acinetobacter baumannii with emerging cefiderocol resistance remains challenging and unclear. We present a case of in vivo emergence of pandrug-resistant A baumannii that was successfully treated with the compassionate use of investigational sulbactam-durlobactam-based antibiotic regimen. We also performed a longitudinal genomic analysis of the bacterial isolates and showed the development of resistance and genetic mutations over time.
Competing Interests: Potential conflicts of interest. S. L. A. serves on the advisory boards for Entasis, GSK, Basilea, bioMérieux, AstraZeneca, Melinta, Shionogi, Ferring, and F2G. S. H. M. is a current employee of Innoviva Specialty Therapeutics, Inc. All other authors report no potential conflicts.
(© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje